Elite Pharmaceuticals Inc (ELTP) financial statements (2020 and earlier)

Company profile

Business Address 165 LUDLOW AVENUE
NORTHVALE, NJ 07647
State of Incorp. NV
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments227111277
Cash and cash equivalents227111277
Receivables3111211
Inventory, net of allowances, customer advances and progress billings4556332
Inventory4556332
Deferred costs    000
Other undisclosed current assets1110000
Total current assets:991418171210
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment8899864
Long-term investments and receivables      3
Long-term investments      3
Intangible assets, net (including goodwill)7786666
Intangible assets, net (excluding goodwill)7786666
Restricted cash and investments     00
Other noncurrent assets000011 
Other undisclosed noncurrent assets     (0)0
Total noncurrent assets:15161716151414
TOTAL ASSETS:24243134322624
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:5532242
Accounts payable11212  
Accrued liabilities44211  
Other undisclosed accounts payable and accrued liabilities     42
Deferred revenue0
Debt1110003
Due to related parties1   11 
Deferred revenue and credits11100
Other undisclosed current liabilities01  001
Total current liabilities:8753556
Noncurrent Liabilities
Long-term debt and lease obligation222222 
Long-term debt, excluding current maturities222222 
Operating lease, liability0
Liabilities, other than long-term debt0122410
Deferred revenue and credits12300
Deferred revenue0
Due to related parties 11    
Other liabilities0000110
Other undisclosed noncurrent liabilities5331105399
Total noncurrent liabilities:7675165699
Total liabilities:15131292161106
Temporary equity, carrying amount 14  44  
Stockholders' equity
Stockholders' equity attributable to parent, including:9(3)526(33)(35)(81)
Preferred stock14      
Common stock1111111
Treasury stock, value(0)(0)(0)(0)(0)(0)(0)
Additional paid in capital150149147164109161144
Accumulated deficit(155)(152)(143)(139)(143)(196)(225)
Other undisclosed stockholders' equity attributable to parent     (0) 
Other undisclosed stockholders' equity  14  0 
Total stockholders' equity:9(3)1826(33)(35)(81)
TOTAL LIABILITIES AND EQUITY:24243134322624

Income statement (P&L) ($ in millions)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
Revenues1487101255
Revenue, net7101255
Cost of revenue(8)(5)(4)(6)(4)(3)(3)
Gross profit:6344821
Operating expenses(9)(12)(13)(11)(16)(19)(7)
Other undisclosed operating income     0 
Operating loss:(3)(9)(9)(7)(8)(17)(5)
Nonoperating income (expense)(3)(1)49745(92)
Other nonoperating income (expense)(3)(1)49  0
Interest and debt expense(0)(0)(0)(0)(0)(0)(1)
Income (loss) from continuing operations before equity method investments, income taxes:(6)(10)(5)2(1)29(98)
Other undisclosed income (loss) from continuing operations before income taxes(0)000001
Income (loss) from continuing operations before income taxes:(7)(10)(5)2(1)29(97)
Income tax benefit 11210 
Other undisclosed income from continuing operations1      
Income (loss) from continuing operations:(6)(9)(4)4(1)29(97)
Loss from discontinued operations (1)     
Other undisclosed loss before gain (loss) on sale of properties(1)      
Income (loss) before gain (loss) on sale of properties:(6)(10)(4)4(1)29(97)
Other undisclosed net loss(0)      
Net income (loss):(6)(10)(4)4(1)29(97)
Other undisclosed net income attributable to parent11    0
Net income (loss) attributable to parent:(6)(9)(4)4(1)29(97)
Other undisclosed net income (loss) available to common stockholders, basic   21(9)  
Net income (loss) available to common stockholders, basic:(6)(9)(4)25(10)29(97)
Other undisclosed net loss available to common stockholders, diluted(1)(0)(5)(30) (44) 
Net loss available to common stockholders, diluted:(7)(9)(8)(6)(10)(15)(97)

Comprehensive Income ($ in millions)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
Net income (loss):(6)(10)(4)4(1)29(97)
Comprehensive income (loss), net of tax, attributable to parent:(6)(10)(4)4(1)29(97)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: